Q4 2024 Earnings Call Transcript February 11, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.63, ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

Phase I clinical trials are the first step in testing a new treatment or combination of treatments. These trials often ...

New packaging solution ensures all take-home products are recyclable through most curb-side programsBELVIDERE, NJ, Feb. 13, ...

Genprex’s (GNPX) research collaborators at a major cancer research center in Houston, Texas have published a new study which used the company’s ...

This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

In a pioneering collaboration with AbbVie, Northwestern researchers have discovered a new way to potentially treat cancer by ...

AI creates anti-cancer molecules for proteins that previously could not be targeted pharmacologically by leveraging quantum ...

Belvidere-based Edible Garden is bringing something new to the table. After a successful pilot production, the hydroponic ...

Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue ...

The research uncovers key genetic mutations that affect cancer treatment responses and develops a predictive tool for ...

Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...